---

Federal Register announcement published November 3, 1995, by the NIH.

---

[Federal Register: October 17, 1995 (Volume 60, Number 200)]
[Notices]
[Page 53792-53793]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 53793]]


The invention listed below is owned by an agency of the U.S.
Government and is available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the U.S. patent
application referenced below may be obtained by contacting Girish C.
Barua, Ph.D., Technology Licensing Specialist, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext
263; fax 301/402-0220). A signed Confidential Disclosure Agreement will
be required to receive a copy of the patent application.

Antibacterial Therapy With Bacteriophage Genotypically Modified To
Delay Inactivation by the Host Defense System

Carlton, R., Merril, C., Adhya, S.
Filed 5 Apr 94
Serial No. 08/222,956

The present invention is directed to bacteriophage therapy, using
methods that enable the bacteriophage to delay inactivation by any and
all parts of the host defense system (HDS) against foreign objects that
would tend to reduce the numbers of bacteriophage and/or the efficiency
of those phage at killing the host bacteria in an infection. Disclosed
is a method of producing bacteriophage modified for anti-HDS purposes,
one method being selection by serial passaging, and the other method
being genetic engineering of a bacteriophage, so that the modified
bacteriophage will remain active in the body for longer periods of time
than the wild-type phage. [portfolio: Infectious Diseases--
Therapeutics]

Dated: October 4, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-25730 Filed 10-16-95; 8:45 am]
BILLING CODE 4140-01-P